Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Trastuzumab Duocarmazine
Synonyms
Therapy Description

SYD985 is an antibody-drug conjugate consisting of the Erbb2 (Her2)-targeting antibody trastuzumab bound to a derivative of the cytotoxic drug duocarmycin, which results in increased death of Erbb2 (Her2)-expressing tumor cells (PMID: 27256376).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Trastuzumab Duocarmazine SYD985|SYD-985|Trastuzumab vc-seco-DUBA|SYD 985 HER2 (ERBB2) Antibody 50 Trastuzumab Duocarmazine (SYD985) is an antibody-drug conjugate consisting of the Erbb2 (Her2)-targeting antibody trastuzumab bound to a derivative of the cytotoxic drug duocarmycin, which results in increased death of Erbb2 (Her2)-expressing tumor cells (PMID: 27256376).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04205630 Phase II Trastuzumab Duocarmazine SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma Recruiting USA 6
NCT03262935 Phase III Capecitabine + Lapatinib Trastuzumab Duocarmazine Eribulin + Trastuzumab Capecitabine + Trastuzumab Trastuzumab + Vinorelbine SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (TULIP) Active, not recruiting USA | CAN 9


Additional content available in CKB BOOST